AI Article Synopsis
- The study investigates the effects of methylphenidate on children and adolescents suffering from difficult-to-treat epilepsies and comorbid ADHD, aiming to evaluate its impact on their quality of life.
- Only one out of 30 patients experienced worsening seizures, and results showed a significant improvement in quality of life, as well as a reduction in seizure frequency and severity after treatment.
- Preliminary data indicates that methylphenidate is safe and effective for this population, positively influencing both seizure management and overall quality of life.
Article Abstract
Objective: Comorbidity between difficult-to-treat epilepsies and ADHD is frequent and impacts negatively on quality of life. The commonly held (yet poorly substantiated) view that stimulants may worsen seizure control has prevented studies from evaluating the impact of such treatment in this population. Our aim was to study the effect of methylphenidate on the quality of life of children and adolescents with difficult-to-treat epilepsies and comorbid ADHD.
Methods: The study was an open-label, noncontrolled trial with intention-to-treat analysis following 30 patients for 6months. Subjects received methylphenidate following 3months of baseline, during which antiepileptic drugs (AEDs) were adjusted and epilepsy, ADHD, and quality-of-life variables were assessed. Multivariate regression analysis identified the main variables correlated with outcome.
Results: Only one patient withdrew because of seizure worsening. Following methylphenidate introduction, doses were titrated up to 0.40-0.50mg/kg/day. A marked improvement in quality-of-life scores and a significant reduction in seizure frequency and severity were observed. Female sex, reduction of core ADHD symptoms, and tolerability to adequate doses of methylphenidate were significantly associated with improved quality-of-life scores.
Conclusion: These preliminary data suggest that methylphenidate treatment is safe and effective in patients with ADHD and difficult-to-treat epilepsies, positively impacting on quality-of-life scores.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yebeh.2015.02.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new?
Expert Rev Neurother
January 2025
Department of Paediatrics, Cambridge University Hospitals, Cambridge, UK.
Introduction: The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) in the US (six in the UK/EU) are licensed for the treatment of seizures in LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not licensed in the UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy and dietary therapies, principally the ketogenic diet and its variants.
View Article and Find Full Text PDFLennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug-resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abnormal electroencephalographic features, and cognitive and behavioral impairments. Management and treatment of LGS are challenging, due to associated comorbidities and the treatment resistance of seizures. A panel of five epileptologists reconvened to provide updated guidance and treatment algorithms for LGS, incorporating recent advancements in antiseizure medications (ASMs) and understanding of DEEs.
View Article and Find Full Text PDFPrimary intracranial malignant melanoma in an adolescent girl with NRAS and TP53 mutations: case report and literature review.
Front Oncol
November 2024
Hebei General Hospital, Shijiazhuang, Hebei, China.
Primary intracranial malignant melanoma(PIMM) is often difficult to treat in patients without a history of skin melanoma or extensive melanin deposition. Due to the rarity of the disease, the current accepted treatment is surgical resection, but the prognosis is still poor. We report a case of PIMM in an adolescent girl with epilepsy as the only symptom and atypical imaging findings.
View Article and Find Full Text PDFExploring ketogenic diet resistance in glucose transporter type 1 deficiency syndrome: A comprehensive review and critical appraisal.
Epilepsia Open
December 2024
Department of Neuropediatrics, University Children's Hospital Zurich, Zurich, Switzerland.
Glucose transporter type 1 deficiency syndrome (GLUT1DS) commonly presents with early-onset epilepsy that often resists conventional pharmacological treatment. Ketogenic diet therapy (KDT) is the preferred approach to address the underlying metabolic anomaly. However, a subset of GLUT1DS patients presents resistance to KDT, with the causes remaining elusive.
View Article and Find Full Text PDFLoss of function variants of are associated with a range of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome. These DEEs feature a wide range of severe neurological disabilities, including changes to social, motor, mood, sleep, and cognitive function which are notoriously difficult to treat, and high rates of early mortality. While the symptomology of -associated DEEs indicates broad changes in neural function, most research has focused on epilepsy-related brain structures and function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!